DURHAM, N.C., June 5, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the Company will host a conference call and webcast on Monday, June 9, 2014 at 1 p.m. EDT. Robert A. Figlin, MD, FACP, professor of medicine and biomedical sciences, director of the Division of Hematology Oncology and deputy director at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, along with Douglas C. Plessinger, RPh, Argos' vice president of clinical and medical affairs, will participate in the call to discuss data recently presented in mRCC at the 2014 ASCO annual meeting held in Chicago, IL from May 30 – June 3, 2014.
Dr. Figlin will review key data in mRCC presented at ASCO, including data from Argos' completed Phase 2 combination study of AGS-003, the Company's investigational fully personalized immunotherapy for cancer. Dr. Figlin will also discuss the progress of Argos' ongoing pivotal Phase 3 ADAPT trial of AGS-003 plus standard targeted therapy.
To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 57270492. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.argostherapeutics.com. Please connect to the Company's website at least 5-10 minutes prior to the live webcast to ensure adequate time for any necessary software download. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company is also developing AGS-004, a personalized immunotherapy for the treatment of HIV, and expects to report data from a Phase 2b trial in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
Source:Argos Therapeutics, Inc.